003220 — Daewon Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩281bn
- KR₩431bn
- KR₩598bn
- 73
- 48
- 46
- 59
Annual cashflow statement for Daewon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 17,198 | 6,611 | 30,657 | 23,463 | 9,045 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 16,515 | 23,703 | 24,937 | 20,532 | 32,712 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -24,435 | -23,813 | -48,549 | -9,822 | -31,817 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 24,951 | 24,307 | 26,413 | 51,734 | 30,035 |
| Capital Expenditures | -15,784 | -11,707 | -13,365 | -20,611 | -53,582 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 891 | -29,908 | -7,410 | -47,656 | 10,607 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -14,893 | -41,615 | -20,775 | -68,267 | -42,975 |
| Financing Cash Flow Items | -1,260 | -1,906 | -3,241 | -4,434 | -6,555 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -12,584 | 48,527 | -20,411 | 19,513 | -298 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2,565 | 31,258 | -14,727 | 3,013 | -12,926 |